Jacobs & Co. CA Has $4.67 Million Stake in Pfizer Inc. $PFE

Key Points

• Jacobs & Co. CA reduced its stake in Pfizer Inc. by 15.8%, holding 192,581 shares valued at approximately $4.67 million.
• Pfizer reported quarterly earnings of $0.78 per share, exceeding analyst expectations, and achieved revenue of $14.65 billion, up 10.3% year-over-year.
• The company announced a quarterly dividend of $0.43 per share, representing an annual yield of 7.2% with a payout ratio of 91.49%.

Jacobs & Co. CA trimmed its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 15.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 192,581 shares of the biopharmaceutical company's stock after selling 36,261 shares during the period. Jacobs & Co. CA's holdings in Pfizer were worth $4,668,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Gould Capital LLC boosted its position in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. bought a new position in Pfizer during the first quarter worth $27,000. North Capital Inc. bought a new position in Pfizer during the first quarter worth $28,000. Bayforest Capital Ltd bought a new position in Pfizer during the first quarter worth $28,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer during the fourth quarter worth $30,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Down 3.8%

PFE opened at $23.91 on Friday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a 50-day simple moving average of $24.79 and a 200 day simple moving average of $24.30. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $135.94 billion, a price-to-earnings ratio of 12.72, a P/E/G ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer's payout ratio is presently 91.49%.

Wall Street Analyst Weigh In

A number of research firms have commented on PFE. Bank of America lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Morgan Stanley boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Jefferies Financial Group boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Berenberg Bank reduced their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Finally, Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.